The Clinical Efficacy And Safety Of Daratumumab In The Treatment Of Relapsed And Refractory Multiple Myeloma

Objective: To evaluate the clinical efficacy,safety and survival of Daratumumab(DARA)in the treatment of relapsed and refractory multiple myeloma(RRMM),and provide realworld data for clinical treatment.Methods: In this study,21 RRMM patients in Shengjing Hospital Affiliated to China Medical University from November 2019 to February 2021 were collected and the followup date was up to February 28,2021.Patients received DARA monotherapy or combination therapy with other drugs.Collect the general information of RRMM patients,the efficacy,adverse reactions and survival status after each chemotherapy cycle.Overall response rate(ORR),complete response(CR)and partial response(PR)were calculated to evaluate the efficacy;Progress free survival(PFS)and overall survival(OS)were calculated to evaluate survival status.Safety was evaluated based on hematology,nonhematology adverse events and infusion related reaction(IRR).Results: 1.21 RRMM patients were enrolled in this study,of which 2 were inconnected after the first cycle treatment,3 died after the first treatment,and 16 patients received efficacy evaluation,the ORR was 62.5%(10/16),of which 43.75%(7/16)of the patients reached PR and even above,and the disease control rate(SD and above)was 93.75%(15/16).Over time,the ORR rate of the third and fourth cycle was higher than that of the first and second cycle.All patients were stratified according to different risk factors,and the best treatment response of patients in different risk factors was compared.There was no statistical difference in ORR rates in different risk factors(p<0.05).2.The median follow-up time was 3.2(0.1-16.2)months.The median PFS was 4.8 months,and the median OS was 7.2 months.3.The most common hematological adverse events are lymphopenia(71.43%),thrombocytopenia(61.91%)and neutropenia(61.90%);the most common non-hematological adverse events are respiratory infections(42.86%),fatigue(71.43%),gastrointestinal reactions(52.38%)and peripheral neuropathy(47.62%).The incidence of IRR was 57.14%,all occurred at the first infusion.Conclusion:1.DARA is a highly effectively therapy for RRMM patients.There is no obvious difference in the efficacy of different risk factors.2.DARA has an acceptable adverse event profile in the treatment of RRMM patients.3.The survival time of our study is lower than that of foreign clinical trials,and further observation is still needed.